Skip to main content

Advertisement

Articles

Page 1 of 15

  1. It has been claimed that the retina can be used as a window to study brain disorders. However, concerning Alzheimer’s disease (AD), it still remains controversial whether changes occurring in the brain and ret...

    Authors: Samuel Chiquita, Elisa J. Campos, João Castelhano, Mário Ribeiro, José Sereno, Paula I. Moreira, Miguel Castelo-Branco and António Francisco Ambrósio

    Citation: Alzheimer's Research & Therapy 2019 11:90

    Content type: Research

    Published on:

  2. The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-β (OAβ) were affected in Alzheimer’s disease (AD) and to examine the associations (or possible correlations) bet...

    Authors: Xue Meng, Tao Li, Xiao Wang, Xiaozhen Lv, Zhiyu Sun, Jichun Zhang, Feng Su, Sungmin Kang, SangYun Kim, Seong Soo A. An, Xin Yu, Chen Zhang and Huali Wang

    Citation: Alzheimer's Research & Therapy 2019 11:89

    Content type: Research

    Published on:

  3. Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and...

    Authors: Dávid Nagy, Lauren Herl Martens, Liza Leventhal, Angela Chen, Craig Kelley, Milan Stoiljkovic and Mihály Hajós

    Citation: Alzheimer's Research & Therapy 2019 11:88

    Content type: Research

    Published on:

  4. Physical activity might reduce the risk of developing dementia. However, it is still unclear whether the protective effect differs depending on the subtype of dementia. We aimed to investigate if midlife physi...

    Authors: Oskar Hansson, Martina Svensson, Anna-Märta Gustavsson, Emelie Andersson, Yiyi Yang, Katarina Nägga, Ulf Hållmarker, Stefan James and Tomas Deierborg

    Citation: Alzheimer's Research & Therapy 2019 11:87

    Content type: Research

    Published on:

  5. Repeated failure of drug candidates targeting Alzheimer’s disease (AD) in clinical trials likely stems from a lack of understanding of the molecular mechanisms underlying AD pathogenesis. Recent research has h...

    Authors: Woo Shik Shin, Jing Di, Qin Cao, Binsen Li, Paul M. Seidler, Kevin A. Murray, Gal Bitan and Lin Jiang

    Citation: Alzheimer's Research & Therapy 2019 11:86

    Content type: Research

    Published on:

  6. Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study...

    Authors: Mary M. Ryan, Joshua D. Grill and Daniel L. Gillen

    Citation: Alzheimer's Research & Therapy 2019 11:85

    Content type: Research

    Published on:

  7. According to the 2018 NIA-AA research framework, Alzheimer’s disease (AD) is not defined by the clinical consequences of the disease, but by its underlying pathology, measured by biomarkers. Evidence of both a...

    Authors: Tiziana Carandini, Andrea Arighi, Luca Sacchi, Giorgio G. Fumagalli, Anna M. Pietroboni, Laura Ghezzi, Annalisa Colombi, Marta Scarioni, Chiara Fenoglio, Milena A. De Riz, Giorgio Marotta, Elio Scarpini and Daniela Galimberti

    Citation: Alzheimer's Research & Therapy 2019 11:84

    Content type: Research

    Published on:

  8. One of the major challenges in diagnosing dementia with Lewy bodies (DLB) is the common co-morbid presence of amyloid pathology. To understand the putative role of altered amyloid-β (Aβ) metabolism in dementia...

    Authors: Inger van Steenoven, Wiesje M. van der Flier, Philip Scheltens, Charlotte E. Teunissen and Afina W. Lemstra

    Citation: Alzheimer's Research & Therapy 2019 11:83

    Content type: Research

    Published on:

  9. Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer’s disea...

    Authors: Simon Sjödin, Gunnar Brinkmalm, Annika Öhrfelt, Lucilla Parnetti, Silvia Paciotti, Oskar Hansson, John Hardy, Kaj Blennow, Henrik Zetterberg and Ann Brinkmalm

    Citation: Alzheimer's Research & Therapy 2019 11:82

    Content type: Research

    Published on:

  10. We aimed to assess the relationship between levels of a cerebrospinal fluid (CSF) marker of pericyte damage, soluble platelet-derived growth factor receptor β (sPDGFRβ) and CSF markers of blood-brain barrier (...

    Authors: J. S. Miners, P. G. Kehoe, S. Love, H. Zetterberg and K. Blennow

    Citation: Alzheimer's Research & Therapy 2019 11:81

    Content type: Research

    Published on:

  11. Up to 20% of patients with AD experience hallucinations. The pathological substrate is not known. Visual hallucinations (VH) are more common in dementia with Lewy bodies (DLB). In autopsy studies, up to 60% of...

    Authors: Lindsey Isla Sinclair, Amit Kumar, Taher Darreh-Shori and Seth Love

    Citation: Alzheimer's Research & Therapy 2019 11:80

    Content type: Research

    Published on:

  12. Very little is known for the direction or causality of the relationship between lifetime sleep experiences and in vivo Alzheimer’s disease (AD) pathologies. This study aimed to examine the relationship between...

    Authors: Young Min Choe, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Bo Kyung Sohn, Yu Kyeong Kim, Seong A Shin, Chul-Ho Sohn, Yu Jin Lee and Dong Young Lee

    Citation: Alzheimer's Research & Therapy 2019 11:79

    Content type: Research

    Published on:

  13. In vivo, high cerebral amyloid-β load has been associated with (i) reduced concentrations of Aβ42 in cerebrospinal fluid and (ii) increased retention using amyloid-β positron emission tomography. Although these t...

    Authors: Arno de Wilde, Juhan Reimand, Charlotte E. Teunissen, Marissa Zwan, Albert D. Windhorst, Ronald Boellaard, Wiesje M. van der Flier, Philip Scheltens, Bart N. M. van Berckel, Femke Bouwman and Rik Ossenkoppele

    Citation: Alzheimer's Research & Therapy 2019 11:78

    Content type: Research

    Published on:

  14. Information given to patients and caregivers during the clinician-patient encounter varies considerably between memory clinic professionals. Patients and caregivers express a clear desire for more information....

    Authors: Agnetha D. Fruijtier, Leonie N. C. Visser, Ingrid S. van Maurik, Marissa D. Zwan, Femke H. Bouwman, Wiesje M. van der Flier and Ellen M. A. Smets

    Citation: Alzheimer's Research & Therapy 2019 11:77

    Content type: Research

    Published on:

  15. The lack of effective treatment options for Alzheimer’s disease (AD) is of momentous societal concern. Synaptic loss is the hallmark of AD that correlates best with impaired memory and occurs early in the dise...

    Authors: Joshua B. Foster, Rashelle Lashley, Fangli Zhao, Xueqin Wang, Nydia Kung, Candice C. Askwith, Lin Lin, Michael W. Shultis, Kevin J. Hodgetts and Chien-Liang Glenn Lin

    Citation: Alzheimer's Research & Therapy 2019 11:75

    Content type: Research

    Published on:

  16. The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was consider...

    Authors: Daniela Bertens, Stephanie Vos, Patrick Kehoe, Henrike Wolf, Flavio Nobili, Alexandre Mendonça, Ineke van Rossum, Jacub Hort, Jose Luis Molinuevo, Michael Heneka, Ron Petersen, Philip Scheltens and Pieter Jelle Visser

    Citation: Alzheimer's Research & Therapy 2019 11:74

    Content type: Research

    Published on:

  17. Mild cognitive impairment (MCI) among an aging global population is a growing challenge for healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate diagnosis ...

    Authors: Jeffrey Cummings, Peter Passmore, Bernadette McGuinness, Vincent Mok, Christopher Chen, Sebastiaan Engelborghs, Michael Woodward, Sagrario Manzano, Guillermo Garcia-Ribas, Stefano Cappa, Paulo Bertolucci and Leung-Wing Chu

    Citation: Alzheimer's Research & Therapy 2019 11:73

    Content type: Review

    Published on:

  18. Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been established as “AD signature”. To what e...

    Authors: Paula M. Petrone, Adrià Casamitjana, Carles Falcon, Miquel Artigues, Grégory Operto, Raffaele Cacciaglia, José Luis Molinuevo, Verónica Vilaplana and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2019 11:72

    Content type: Research

    Published on:

  19. Alzheimer’s disease (AD) is the most common form of dementia. This neurodegenerative disorder is associated with neuronal death and gliosis heavily impacting the cerebral cortex. AD has a substantial but heter...

    Authors: Jorge L. Del-Aguila, Zeran Li, Umber Dube, Kathie A. Mihindukulasuriya, John P. Budde, Maria Victoria Fernandez, Laura Ibanez, Joseph Bradley, Fengxian Wang, Kristy Bergmann, Richard Davenport, John C. Morris, David M. Holtzman, Richard J. Perrin, Bruno A. Benitez, Joseph Dougherty…

    Citation: Alzheimer's Research & Therapy 2019 11:71

    Content type: Research

    Published on:

  20. Alzheimer’s disease may compromise several musical competences, though no clear data is available in the scientific literature. Furthermore, music is capable of communicating basic emotions, but little is know...

    Authors: Eva M. Arroyo-Anlló, Stéphanie Dauphin, M. Noelle Fargeau, Pierre Ingrand and Roger Gil

    Citation: Alzheimer's Research & Therapy 2019 11:69

    Content type: Research

    Published on:

  21. Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assis...

    Authors: Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Christopher Lines and David Michelson

    Citation: Alzheimer's Research & Therapy 2019 11:68

    Content type: Research

    Published on:

  22. Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal mo...

    Authors: Matthias Brendel, Maximilian Deussing, Tanja Blume, Lena Kaiser, Federico Probst, Felix Overhoff, Finn Peters, Barbara von Ungern-Sternberg, Sergey Ryazanov, Andrei Leonov, Christian Griesinger, Andreas Zwergal, Johannes Levin, Peter Bartenstein, Igor Yakushev, Paul Cumming…

    Citation: Alzheimer's Research & Therapy 2019 11:67

    Content type: Research

    Published on:

  23. Subjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer’s disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with in...

    Authors: Lisa Miebach, Steffen Wolfsgruber, Alexandra Polcher, Oliver Peters, Felix Menne, Katja Luther, Enise Incesoy, Josef Priller, Eike Spruth, Slawek Altenstein, Katharina Buerger, Cihan Catak, Daniel Janowitz, Robert Perneczky, Julia Utecht, Christoph Laske…

    Citation: Alzheimer's Research & Therapy 2019 11:66

    Content type: Research

    Published on:

  24. Late-onset Alzheimer’s disease (AD) is characterized by primary memory impairment, which then progresses towards severe deficits across cognitive domains. Here, we report how performance in cognitive domains r...

    Authors: Leonardino A. Digma, John R. Madsen, Emilie T. Reas, Anders M. Dale, James B. Brewer and Sarah J. Banks

    Citation: Alzheimer's Research & Therapy 2019 11:65

    Content type: Research

    Published on:

  25. Longitudinal investigations are needed to improve understanding of the contributions of cerebral small vessel disease to the clinical manifestation of Alzheimer’s disease, particularly in the early disease sta...

    Authors: Christian Puzo, Caroline Labriola, Michael A. Sugarman, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Thor D. Stein, Neil W. Kowall, Ann C. McKee, Jesse Mez, Ronald J. Killiany, Robert A. Stern and Michael L. Alosco

    Citation: Alzheimer's Research & Therapy 2019 11:64

    Content type: Research

    Published on:

  26. Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer’s disease (AD). Retinal thinning is hypothesized to be a...

    Authors: Jurre den Haan, Lajos Csinscik, Tom Parker, Ross W. Paterson, Catherine F. Slattery, Alexander Foulkes, Femke H. Bouwman, Frank D. Verbraak, Philip Scheltens, Tunde Peto, Imre Lengyel, Jonathan M. Schott, Sebastian J. Crutch, Timothy J. Shakespeare and Keir X. X. Yong

    Citation: Alzheimer's Research & Therapy 2019 11:62

    Content type: Research

    Published on:

  27. Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer’s disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a m...

    Authors: Elizabeth Kuhn, Inès Moulinet, Audrey Perrotin, Renaud La Joie, Brigitte Landeau, Clémence Tomadesso, Alexandre Bejanin, Siya Sherif, Vincent De La Sayette, Béatrice Desgranges, Denis Vivien, Géraldine Poisnel and Gaëlle Chételat

    Citation: Alzheimer's Research & Therapy 2019 11:61

    Content type: Research

    Published on:

  28. Neuropathological studies have linked tau aggregates to neuronal loss. To describe the spatial distribution of neurofibrillary tangle pathology in post-mortem tissue, Braak staging has been used. The aim of th...

    Authors: Tessa Timmers, Rik Ossenkoppele, Emma E. Wolters, Sander C. J. Verfaillie, Denise Visser, Sandeep S. V. Golla, Frederik Barkhof, Philip Scheltens, Ronald Boellaard, Wiesje M. van der Flier and Bart N. M. van Berckel

    Citation: Alzheimer's Research & Therapy 2019 11:60

    Content type: Research

    Published on:

  29. The earliest brain pathology related to Alzheimer’s disease (AD) is hyperphosphorylated soluble tau in the noradrenergic locus coeruleus (LC) neurons. Braak characterizes five pretangle tau stages preceding AD...

    Authors: Abhinaba Ghosh, Sarah E. Torraville, Bandhan Mukherjee, Susan G. Walling, Gerard M. Martin, Carolyn W. Harley and Qi Yuan

    Citation: Alzheimer's Research & Therapy 2019 11:59

    Content type: Research

    Published on:

  30. Tau stabilizes microtubules; however, in Alzheimer’s disease (AD) and tauopathies, tau becomes hyperphosphorylated, aggregates, and results in neuronal death. Our group recently uncovered a unique interaction ...

    Authors: Leslie A. Sandusky-Beltran, Andrii Kovalenko, Chao Ma, John Ivan T. Calahatian, Devon S. Placides, Mallory D. Watler, Jerry B. Hunt, April L. Darling, Jeremy D. Baker, Laura J. Blair, Mackenzie D. Martin, Sarah N. Fontaine, Chad A. Dickey, April L. Lussier, Edwin J. Weeber, Maj-Linda B. Selenica…

    Citation: Alzheimer's Research & Therapy 2019 11:58

    Content type: Research

    Published on:

  31. Reduced 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer’s disease (AD) biolog...

    Authors: Ya-Nan Ou, Wei Xu, Jie-Qiong Li, Yu Guo, Mei Cui, Ke-Liang Chen, Yu-Yuan Huang, Qiang Dong, Lan Tan and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2019 11:57

    Content type: Research

    Published on:

  32. Intracerebral inoculation of extracts from post-mortem human Alzheimer’s disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the sy...

    Authors: Cristina M. Pedrero-Prieto, Alicia Flores-Cuadrado, Daniel Saiz-Sánchez, Isabel Úbeda-Bañón, Javier Frontiñán-Rubio, Francisco J. Alcaín, Lourdes Mateos-Hernández, José de la Fuente, Mario Durán-Prado, Margarita Villar, Alino Martínez-Marcos and Juan R. Peinado

    Citation: Alzheimer's Research & Therapy 2019 11:56

    Content type: Research

    Published on:

  33. Age-related frailty reflects cumulative multisystem physiological and health decline. Frailty increases the risk of adverse brain and cognitive outcomes, including differential decline and dementia. In a longi...

    Authors: Sherilyn Thibeau, Kirstie McDermott, G. Peggy McFall, Kenneth Rockwood and Roger A. Dixon

    Citation: Alzheimer's Research & Therapy 2019 11:55

    Content type: Research

    Published on:

  34. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine. Chronic inflammation induced by amyloid β proteins (Aβ) is one prominent neuropathological feature in Alzheimer’s disease (AD) brain.

    Authors: Si Zhang, Jiehao Zhao, Yuhu Zhang, Yun Zhang, Fang Cai, Lijuan Wang and Weihong Song

    Citation: Alzheimer's Research & Therapy 2019 11:54

    Content type: Research

    Published on:

  35. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimo...

    Authors: Ruth Stephen, Yawu Liu, Tiia Ngandu, Riitta Antikainen, Juha Hulkkonen, Juha Koikkalainen, Nina Kemppainen, Jyrki Lötjönen, Esko Levälahti, Riitta Parkkola, Pauliina Pippola, Juha Rinne, Timo Strandberg, Jaakko Tuomilehto, Ritva Vanninen, Miia Kivipelto…

    Citation: Alzheimer's Research & Therapy 2019 11:53

    Content type: Research

    Published on:

  36. Authors: Carl Taswell, Cheryl Donohue, Maree T. Mastwyk, Andrea G. Louey, Jacqueline Giummarra, Joanne Robertson, David G. Darby, Colin L. Masters and Christopher C. Rowe

    Citation: Alzheimer's Research & Therapy 2019 11:52

    Content type: Letter

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2018 10:125

    The Letter Response to this article has been published in Alzheimer's Research & Therapy 2019 11:51

  37. Subjective cognitive decline (SCD) is characterized by self-reported cognitive deficits without measurable cognitive impairment. It has been suggested that individuals with SCD exhibited brain structural alter...

    Authors: Yu Sun, Xiaoni Wang, Yinshan Wang, Haoming Dong, Jie Lu, Tohar Scheininger, Michael Ewers, Frank Jessen, Xi-Nian Zuo and Ying Han

    Citation: Alzheimer's Research & Therapy 2019 11:50

    Content type: Research

    Published on:

  38. Alzheimer’s disease (AD) prevalence is rapidly growing as worldwide populations grow older. Available treatments have failed to slow down disease progression, thus increasing research focus towards early or pr...

    Authors: David López-Sanz, Ricardo Bruña, María Luisa Delgado-Losada, Ramón López-Higes, Alberto Marcos-Dolado, Fernando Maestú and Stefan Walter

    Citation: Alzheimer's Research & Therapy 2019 11:49

    Content type: Research

    Published on:

  39. Neuropsychiatric symptoms (NPS) are very common in patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia and are associated with various disadvantageous clinical outcomes includin...

    Authors: Willem S. Eikelboom, Ellen Singleton, Esther van den Berg, Michiel Coesmans, Francesco Mattace Raso, Rozemarijn L. van Bruchem, Jeannette A. Goudzwaard, Frank Jan de Jong, Marc Koopmanschap, Tom den Heijer, Jan J. M. Driesen, Lilian J. H. M. Vroegindeweij, Elsbeth C. Thomeer, Susanne E. Hoogers, Anke A. Dijkstra, Sytse U. Zuidema…

    Citation: Alzheimer's Research & Therapy 2019 11:48

    Content type: Research

    Published on:

  40. There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefor...

    Authors: Nienke Legdeur, Sven J. van der Lee, Marcel de Wilde, Johan van der Lei, Majon Muller, Andrea B. Maier and Pieter Jelle Visser

    Citation: Alzheimer's Research & Therapy 2019 11:47

    Content type: Research

    Published on:

  41. Several evidences suggest that failure of synaptic function occurs at preclinical stages of Alzheimer’s disease (AD) preceding neuronal loss and the classical AD pathological hallmarks. Nowadays, there is an u...

    Authors: Dolores Siedlecki-Wullich, Judit Català-Solsona, Cristina Fábregas, Isabel Hernández, Jordi Clarimon, Alberto Lleó, Merce Boada, Carlos A. Saura, José Rodríguez-Álvarez and Alfredo J. Miñano-Molina

    Citation: Alzheimer's Research & Therapy 2019 11:46

    Content type: Research

    Published on:

  42. The cognitive-functional composite (CFC) was designed to improve the measurement of clinically relevant changes in predementia and early dementia stages. We have previously demonstrated its good test-retest re...

    Authors: Roos J. Jutten, John E. Harrison, Philippe R. Lee Meeuw Kjoe, Silvia Ingala, R. Vreeswijk, R. A. J. van Deelen, Frank Jan de Jong, Esther M. Opmeer, André Aleman, Craig W. Ritchie, Philip Scheltens and Sietske A. M. Sikkes

    Citation: Alzheimer's Research & Therapy 2019 11:45

    Content type: Research

    Published on:

  43. Alzheimer’s disease (AD) is defined by amyloid beta (Aβ) plaques and neurofibrillary tangles and characterized by neurodegeneration and memory loss. The majority of AD patients also have Aβ deposition in cereb...

    Authors: Emily B. Button, Guilaine K. Boyce, Anna Wilkinson, Sophie Stukas, Arooj Hayat, Jianjia Fan, Brennan J. Wadsworth, Jerome Robert, Kris M. Martens and Cheryl L. Wellington

    Citation: Alzheimer's Research & Therapy 2019 11:44

    Content type: Research

    Published on:

  44. Studies in older adults or those with cognitive impairment have shown associations between cognitive and olfactory performance, but there are few population-based studies especially in younger adults. We there...

    Authors: Maryam Yahiaoui-Doktor, Tobias Luck, Steffi G. Riedel-Heller, Markus Loeffler, Kerstin Wirkner and Christoph Engel

    Citation: Alzheimer's Research & Therapy 2019 11:43

    Content type: Research

    Published on:

  45. ApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in β-amyloid (Aβ) fibrillization and clearance in the context of Alzheimer’s disease has been widely studied, ...

    Authors: Sofía Fernández de Retana, Paula Marazuela, Montse Solé, Guillem Colell, Anna Bonaterra, Jose Luis Sánchez-Quesada, Joan Montaner, Daniel Maspoch, Mary Cano-Sarabia and Mar Hernández-Guillamon

    Citation: Alzheimer's Research & Therapy 2019 11:42

    Content type: Research

    Published on:

  46. Oligomeric amyloid-ß is a major toxic species associated with Alzheimer’s disease pathogenesis. Methods used to measure oligomeric amyloid-β in the blood have increased in number in recent years. The Multimer ...

    Authors: Young Chul Youn, Sungmin Kang, Jeewon Suh, Young Ho Park, Min Ju Kang, Jung-Min Pyun, Seong Hye Choi, Jee Hyang Jeong, Kyung Won Park, Ho-Won Lee, Seong Soo A. An, Jacqueline C. Dominguez and SangYun Kim

    Citation: Alzheimer's Research & Therapy 2019 11:40

    Content type: Research

    Published on: